



US 20210300872A1

(19) **United States**(12) **Patent Application Publication** (10) **Pub. No.: US 2021/0300872 A1**
(43) **Pub. Date: Sep. 30, 2021**(54) **SECOND GENERATION GRP94-SELECTIVE INHIBITORS**

(60) Provisional application No. 62/550,292, filed on Aug. 25, 2017.

(71) Applicant: **University of Kansas**, Lawrence, KS (US)**Publication Classification**(72) Inventors: **Brian S.J. Blagg**, Niles, MI (US);
Vincent Matthew Crowley, Lawrence, KS (US)(51) **Int. Cl.**
C07D 213/643 (2006.01)
C07C 69/78 (2006.01)
C07C 219/34 (2006.01)(21) Appl. No.: **17/341,047**(52) **U.S. Cl.**
CPC **C07D 213/643** (2013.01); **C07C 219/34** (2013.01); **C07C 69/78** (2013.01)(22) Filed: **Jun. 7, 2021**(57) **ABSTRACT****Related U.S. Application Data**

(63) Continuation of application No. 16/640,897, filed on Feb. 21, 2020, now Pat. No. 11,028,041, filed as application No. PCT/US2018/047820 on Aug. 23, 2018.

The present technology provides compounds selective for the Grp94 isoform, as well as compositions including such compounds, that are useful for treatment of multiple myeloma, melanoma, lung cancer, hepatocellular carcinoma, breast cancer, prostate cancer, and/or glaucoma. Methods using the compound are also provided.

